BioNTech (NASDAQ:BNTX) Posts Earnings Results, Misses Estimates By $0.19 EPS

Key Points

• BioNTech reported a **quarterly loss of $1.82** per share, missing the consensus estimate by **$0.44**.
• The company's stock has a market capitalization of **$25.80 billion** and currently has a consensus price target of **$136.58** from analysts.
• Institutional investors hold **15.52%** of BioNTech's stock, highlighting growing interest from larger financial entities.

BioNTech (NASDAQ:BNTX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19), Briefing.com reports. BioNTech had a negative return on equity of 3.94% and a negative net margin of 27.37%. The company had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. During the same period in the previous year, the business earned ($3.36) earnings per share. BioNTech's revenue was up 102.6% on a year-over-year basis. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Trading Up 3.0%

Shares of NASDAQ BNTX traded up $3.22 during trading hours on Monday, hitting $110.56. The company's stock had a trading volume of 505,621 shares, compared to its average volume of 949,449. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The stock has a market cap of $26.58 billion, a price-to-earnings ratio of -32.52 and a beta of 1.23. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The business has a 50-day simple moving average of $108.11 and a 200-day simple moving average of $106.17.

Institutional Trading of BioNTech

A hedge fund recently raised its stake in BioNTech stock. Royal Bank of Canada increased its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 95.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,177 shares of the company's stock after purchasing an additional 3,514 shares during the quarter. Royal Bank of Canada's holdings in BioNTech were worth $653,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BNTX. JPMorgan Chase & Co. lowered their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Citigroup restated a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $138.00 price target on shares of BioNTech in a research report on Wednesday, June 25th. Finally, Morgan Stanley raised their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $136.58.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.